文献速递淋巴瘤造血干细胞移植与细胞治疗

利基迈仑赛对复发/难治性大B细胞淋巴瘤健康相关生活质量与症状严重程度的影响

Effect of lisocabtagene maraleucel on HRQoL and symptom severity in relapsed/refractory large B-cell lymphoma.
PubMed 文献 · Blood Adv · 2021-01-01

在TRANSCEND NHL 001开放标签非随机试验中,采用EORTC QLQ-C30和EQ-5D-5L评估liso-cel治疗复发/难治性大B细胞淋巴瘤患者的生活质量与症状。liso-cel输注后2至18个月全球健康状况/QoL出现临床意义改善,疲劳在2、12、18个月有临床意义改善,且改善与抗肿瘤活性相关。

要点

  • liso-cel输注后2至18个月全球健康状况/QoL出现临床意义改善(基于10分最小重要差异)。
  • 疲劳在输注后2、12、18个月出现临床意义改善,躯体功能和疼痛无临床意义变化。
  • 治疗应答者全球健康状况/QoL临床意义改善比例总体高于非应答者。

核心结论

  • liso-cel治疗复发/难治性LBCL患者可出现早期、持续且临床意义的生活质量与症状改善,并与抗肿瘤活性相关。

研究设计与样本

  • 正在进行的开放标签、非随机TRANSCEND NHL 001试验(NCT02631044),使用EORTC QLQ-C30和EQ-5D-5L评估liso-cel治疗复发/难治性LBCL患者。

主要发现

  • EORTC QLQ-C30全球健康状况/QoL评分在liso-cel输注后2至18个月出现临床意义改善,基于10分最小重要差异。
  • 躯体功能和疼痛无临床意义变化,疲劳在2、12、18个月出现临床意义改善。
  • 全球健康状况/QoL临床意义改善的患者比例在治疗应答者中总体高于非应答者。
  • EQ-5D-5L指数平均分在输注后1个月呈下降趋势,随后至18个月上升;EQ-5D-5L视觉模拟量表平均分从2个月至18个月上升。

临床怎么用

  • 对于复发/难治性LBCL患者,liso-cel治疗除抗肿瘤活性外,还可带来生活质量与疲劳等症状的早期持续改善。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CD19-directed chimeric antigen receptor (CAR) T-cell therapy has shown efficacy as a third-line or later treatment in patients with relapsed/refractory large B-cell lymphoma (LBCL). Using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) and the EuroQol 5-Dimension 5-Level (EQ-5D-5L) questionnaire, we evaluated the impact of CAR T-cell treatment with lisocabtagene maraleucel (liso-cel) on health-related quality of life (HRQoL) and symptoms in patients with relapsed/refractory LBCL in the ongoing, open-label, nonrandomized TRANSCEND NHL 001 trial. Clinically meaningful improvement was observed in EORTC QLQ-C30 scores for global health status/QoL, based on a minimally important difference of 10 points at 2 to 18 months after liso-cel infusion. There were no clinically meaningful changes in physical functioning and pain, whereas clinically meaningful improvements were observed in fatigue at 2, 12, and 18 months. The proportion of patients with clinically meaningful improvement in global health status/QoL was generally higher for treatment responders than for nonresponders. A trend toward decreased mean EQ-5D-5L index scores was observed at 1 month after liso-cel infusion, followed by subsequent increases through 18 months. Mean EQ-5D-5L visual analog scale scores increased from 2 through 18 months. In summary, patients with relapsed/refractory LBCL treated with liso-cel had early, sustained, and clinically meaningful improvements in HRQoL and symptoms that correlated with antitumor activity. This study was registered at www.clinicaltrials.gov as #NCT02631044.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Patrick DL, Powers A, Jun MP, et al. Effect of lisocabtagene maraleucel on HRQoL and symptom severity in relapsed/refractory large B-cell lymphoma. Blood Adv. 2021. PMID: 33904895. doi:10.1182/bloodadvances.2020003503

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。